{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:15:17Z","timestamp":1793812517925,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lungcan.2024.107820","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:22:04Z","timestamp":1715354524000},"page":"107820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"192","author":[{"given":"Enriqueta","family":"Felip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Metro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-7534","authenticated-orcid":false,"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Tiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feby I.","family":"Mardjuadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-1144","authenticated-orcid":false,"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2024.107820_b0005","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.lungcan.2024.107820_b0010","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1038\/s41388-020-1193-8","article-title":"MET targeting: time for a rematch","volume":"39","author":"Koch","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107820_b0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107820_b0020","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107820_b0025","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers6031540","article-title":"Targeting MET amplification as a new oncogenic driver","volume":"6","author":"Kawakami","year":"2014","journal-title":"Cancers (basel)"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107820_b0030","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107820_b0035","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.cllc.2018.03.010","article-title":"MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy","volume":"19","author":"Reis","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107820_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113595","article-title":"HGF\/MET and the immune system: relevance for cancer immunotherapy","volume":"19","author":"Papaccio","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2024.107820_b0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2020.00054","article-title":"The emerging role of the c-MET-HGF axis in non-small cell lung cancer tumor immunology and immunotherapy","volume":"10","author":"Titmarsh","year":"2020","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107820_b0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107820_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2021.10.025","article-title":"Targeting c-Met to improve immune checkpoint inhibition in metastatic renal cell carcinoma","volume":"81","author":"Lindner","year":"2022","journal-title":"Eur. Urol."},{"issue":"17","key":"10.1016\/j.lungcan.2024.107820_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174287","article-title":"MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function","volume":"20","author":"Ahn","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107820_b0065","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.21037\/tlcr-21-124","article-title":"Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?-a narrative review","volume":"10","author":"Dempke","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107820_b0070","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107820_b0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","article-title":"Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers","volume":"88","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"issue":"33","key":"10.1016\/j.lungcan.2024.107820_b0080","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107820_b0085","doi-asserted-by":"crossref","first-page":"TPS9134","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9134","article-title":"CONTACT-01: a phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1\/PD-1 inhibitors and platinum-containing chemotherapy","volume":"39","author":"Neal","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107820_b0090","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1200\/JCO.2020.38.15_suppl.9610","article-title":"Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study","volume":"38","author":"Neal","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107820_b0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107820_b0100","doi-asserted-by":"crossref","unstructured":"J. Wolf, T. Seto, J.Y. Han, N. Reguart, E.B. Garon, H.J.M. Groen, D.S.W. Tan, T. Hida, M. de Jonge, S.V. Orlov, E.F. Smit, P.J. Souquet, J. Vansteenkiste, M. Hochmair, E. Felip, M. Nishio, M. Thomas, K. Ohashi, R. Toyozawa, T.R. Overbeck, F. de Marinis, T.M. Kim, E. Laack, A. Robeva, S. Le Mouhaer, M. Waldron-Lynch, B. Sankaran, O.A. Balbin, X. Cui, M. Giovannini, M. Akimov, R.S. Heist, G.m.-. Investigators, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, N Engl J Med 383(10) (2020) 944-957.","DOI":"10.1056\/NEJMoa2002787"},{"key":"10.1016\/j.lungcan.2024.107820_b0105","unstructured":"Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213591s002lbl.pdf. Revised January 2022. Accessed June 10, 2022."},{"key":"10.1016\/j.lungcan.2024.107820_b0110","unstructured":"Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125554s106lbl.pdf. Revised May 2022. Accessed June 10, 2022."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107820_b0115","first-page":"723","volume":"39","author":"Borghaei","year":"2021","journal-title":"J."},{"key":"10.1016\/j.lungcan.2024.107820_b0120","doi-asserted-by":"crossref","unstructured":"J. Brahmer, K.L. Reckamp, P. Baas, L. Crino, W.E. Eberhardt, E. Poddubskaya, S. Antonia, A. Pluzanski, E.E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Aren Frontera, L. Havel, M. Steins, M.C. Garassino, J.G. Aerts, M. Domine, L. Paz-Ares, M. Reck, C. Baudelet, C.T. Harbison, B. Lestini, D.R. Spigel, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med 373(2) (2015) 123-35.","DOI":"10.1056\/NEJMoa1504627"},{"key":"10.1016\/j.lungcan.2024.107820_b0125","doi-asserted-by":"crossref","unstructured":"H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow, E.E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaufl, O. Arrieta, M.A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin, N. Rizvi, L. Crino, G.R. Blumenschein, Jr., S.J. Antonia, C. Dorange, C.T. Harbison, F. Graf Finckenstein, J.R. Brahmer, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med 373(17) (2015) 1627-39.","DOI":"10.1056\/NEJMoa1507643"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107820_b0130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2213-2600(19)30267-X","article-title":"Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study","volume":"8","author":"Tan","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107820_b0135","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/0008-5472.CAN-15-2581","article-title":"EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor","volume":"76","author":"Jia","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107820_b0140","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejca.2022.05.023","article-title":"Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study","volume":"172","author":"Tan","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107820_b0145","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1200\/JCO.2020.38.15_suppl.10048","article-title":"Clinical outcomes with early-elective discontinuation of PD-1 inhibitors (PDi) at one year in patients (pts) with metastatic melanoma (MM)","volume":"38","author":"Pokorny","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2024.107820_b0150","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.lungcan.2024.107820_b0155","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107820_b0160","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.lungcan.2024.107820_b0165","doi-asserted-by":"crossref","first-page":"S1007","DOI":"10.1016\/j.annonc.2022.07.1120","article-title":"994P Efficacy and safety of capmatinib plus spartalizumab in treatment-na\u00efve patients with advanced NSCLC harboring MET exon 14 skipping mutation","volume":"33","author":"Wolf","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107820_b0170","series-title":"Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-na\u00efve patients with advanced non\u2013small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study","author":"Mok","year":"2022"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:11:19Z","timestamp":1717539079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"alternative-id":["S0169500224003544"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107820","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107820"}}